These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 2829291

  • 1. Autoradiographic localization of vasoactive intestinal peptide (VIP) binding sites in the human term placenta. Relationship with activation of adenylate cyclase.
    Besson J, Malassiné A, Ferré F.
    Regul Pept; 1987 Nov; 19(3-4):197-207. PubMed ID: 2829291
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
    Gespach C, Bawab W, de Cremoux P, Calvo F.
    Cancer Res; 1988 Sep 15; 48(18):5079-83. PubMed ID: 2842044
    [Abstract] [Full Text] [Related]

  • 3. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
    Le Meuth V, Farjaudon N, Bawab W, Chastre E, Rosselin G, Guilloteau P, Gespach C.
    Am J Physiol; 1991 Feb 15; 260(2 Pt 1):G265-74. PubMed ID: 1847591
    [Abstract] [Full Text] [Related]

  • 4. Interaction of vasoactive intestinal peptide with a cell line (HeLa) derived from human carcinoma of the cervix: binding to specific sites and stimulation of adenylate cyclase.
    Prieto JC, Guerrero JM, de Miguel C, Goberna R.
    Mol Cell Biochem; 1981 Jul 15; 37(3):167-76. PubMed ID: 6268963
    [Abstract] [Full Text] [Related]

  • 5. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL, O'Dorisio MS, Vassalo LM, Malarkey WB, O'Dorisio TM.
    Regul Pept; 1985 Nov 07; 12(3):237-48. PubMed ID: 3001842
    [Abstract] [Full Text] [Related]

  • 6. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
    Robberecht P, Coy DH, De Neef P, Camus JC, Cauvin A, Waelbroeck M, Christophe J.
    Eur J Biochem; 1987 Jun 01; 165(2):243-9. PubMed ID: 3036504
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
    Moretti C, Bagnato A, Solan N, Frajese G, Catt KJ.
    Endocrinology; 1990 Nov 01; 127(5):2117-26. PubMed ID: 2171907
    [Abstract] [Full Text] [Related]

  • 13. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
    Martin JM, Luis J, Marvaldi J, Pichon J, Pic P.
    Eur J Biochem; 1989 Mar 15; 180(2):435-9. PubMed ID: 2538331
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology.
    Christophe J, Waelbroeck M, Chatelain P, Robberecht P.
    Peptides; 1984 Mar 15; 5(2):341-53. PubMed ID: 6089134
    [Abstract] [Full Text] [Related]

  • 16. Binding of vasoactive intestinal peptide and its stimulation of adenylate cyclase through two classes of receptors in rat liver membranes. Effects of 12 secretin analogues and 2 secretin fragments.
    Waelbroeck M, Robberecht P, De Neef P, Chatelain P, Christophe J.
    Biochim Biophys Acta; 1981 Nov 18; 678(1):83-90. PubMed ID: 6272875
    [Abstract] [Full Text] [Related]

  • 17. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68.
    Van Valen F, Jürgens H, Winkelmann W, Keck E.
    Cell Signal; 1989 Nov 18; 1(5):435-46. PubMed ID: 2561912
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V, Kienlen-Campard P, Loeffler JP, Basille M, Gonzalez BJ, Vaudry H, Robberecht P, Pévet P.
    Neuroscience; 1998 Aug 18; 85(3):887-96. PubMed ID: 9639281
    [Abstract] [Full Text] [Related]

  • 19. The effect of vasoactive intestinal peptide (VIP) on the contractile activity of human uterine smooth muscle.
    Leroy MJ, Tanguy G, Vial M, Rostène W, Malassiné A, Ferré F.
    Clin Exp Pharmacol Physiol; 1991 Apr 18; 18(4):205-15. PubMed ID: 1649025
    [Abstract] [Full Text] [Related]

  • 20. Cerebral vascular adenylate cyclase: evidence for coupling to receptors for vasoactive intestinal peptide and parathyroid hormone.
    Huang M, Rorstad OP.
    J Neurochem; 1984 Sep 18; 43(3):849-56. PubMed ID: 6086840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.